Clinical Trial Update: Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. [Phase 1]

View source ↗

Summary

Phase I open-label study assessing the safety of combining afatinib with trastuzumab in patients with HER2-positive advanced breast cancer; results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afatinib (afatinib)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2013-10-17